Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine plus megestrol acetate for gastrointestinal cancer cachexia
IRCT20090613002027N23Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cancer anorexia-cachexia syndrome (CACS) and gastrointestinal cancer comparing Mirtazapine + megestrol acetate with Placebo + megestrol acetate (2 arms). Primary endpoints: Weight gain, Cachexia and 5 more. Started Oct 2024; status: completed.
02
Drugs
mirtazapinemegestrol
03
Conditions
cancer anorexia-cachexia syndrome (CACS)gastrointestinal cancer
Beyond the preview
Go deeper on IRCT20090613002027N23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090613002027N23.